Primary malignant bone neoplasm: a case report of dedifferentiated chondrosarcoma in the rib and review of the literature.
Dedifferentiated chondrosarcoma (DDCS) is a rare but highly malignant primary bone neoplasm, which is resistant to radiotherapy and chemotherapy. There remains uncertainly as to the best treatment of this disease and how to improve its prognosis. In this paper we reported a case of DDCS and reviewed the related literatures in order to provide references to throw a light on the histogenesis, diagnosis and therapy of this disease.
Lin
Jin-Rong
JR
Oncology Department, Guangzhou General Hospital of PLA, Guangzhou, Guangdong 510010, PR China.
Zhang
Wei-Min
WM
Wang
Zhuo-Cai
ZC
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D002813:Chondrosarcoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006390:Hemangioendothelioma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D012272:Ribs; D014057:Tomography, X-Ray Computed
D004317:Doxorubicin; C027260:pirarubicin; D002945:Cisplatin; D008727:Methotrexate